Gillian Dekkers

Gillian Dekkers

Auto-generated profile, based on publicly available information

Gillian Dekkers

QVQ Holding BV, Universiteitsweg 101, 3584 CG Utrecht, the Netherlands

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
GDGillian Dekkers
Gillian Dekkers
TRTheo Rispens
Theo Rispens
Of the five immunoglobulin isotypes, Immunoglobulin G (IgG) is most abundant in human serum. The four subclasses, IgG1, IgG2, IgG3 and IgG4 which are highly conserved, differ in their constant region, particularly in their hinges and upper CH2 domains. These regions are involved in binding to both IgG-Fc receptor (FcγR) and C1q. As a result, the different subclasses have different effector functions, both in terms of triggering FcγR-expressing cells, resulting in phagocytosis or Antibody-dependent cell-mediated cytotoxicity (ADCC), and activating complement. The Fc-regions also contain a binding epitope for the neonatal Fc-receptor (FcRn), responsible for the extended half-life, placental transport, and bidirectional transport of IgG to mucosal surfaces. However, FcRn is also expressed in myeloid cells, where it participates in both phagocytosis and antigen presentation together with classical FcγR and complement. How these properties, IgG-polymorphisms and post-translational modification of the antibodies in the form of glycosylation, affect IgG-function, will be the focus of the current review.

2 August 2017 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
GDGillian Dekkers
Gillian Dekkers
LTLouise Treffers
Louise Treffers
RPRosina Plomp
Rosina Plomp
ABArthur E. H. Bentlage
Arthur E. H. Bentlage
MBMarcella de Boer
Marcella de Boer
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
Glycosylation of the immunoglobulin G (IgG)-Fc tail is required for binding to Fc-gamma receptors (FcγRs) and complement-component C1q. A variety of IgG1-glycoforms is detected in human sera. Several groups have found global or antigen-specific skewing of IgG glycosylation, for example in autoimmune diseases, viral infections, and alloimmune reactions. The IgG glycoprofiles seem to correlate with disease outcome. Additionally, IgG-glycan composition contributes significantly to Ig-based therapies, as for example IVIg in autoimmune diseases and therapeutic antibodies for cancer treatment. The effect of the different glycan modifications, especially of fucosylation, has been studied before. However, the contribution of the 20 individual IgG glycoforms, in which the combined effect of all 4 modifications, to the IgG function has never been investigated. Here, we combined six glyco-engineering methods to generate all 20 major human IgG1-glycoforms and screened their functional capacity for FcγR and complement activity. Bisection had no effect on FcγR or C1q-binding, and sialylation had no- or little effect on FcγR binding. We confirmed that hypo-fucosylation of IgG1 increased binding to FcγRIIIa and FcγRIIIb by ~17-fold, but in addition we showed that this effect could be further increased to ~40-fold for FcγRIIIa upon simultaneous hypo-fucosylation and hyper-galactosylation, resulting in enhanced NK cell-mediated antibody-dependent cellular cytotoxicity. Moreover, elevated galactosylation and sialylation significantly increased (independent of fucosylation) C1q-binding, downstream complement deposition, and cytotoxicity. In conclusion, fucosylation and galactosylation are primary mediators of functional changes in IgG for FcγR- and complement-mediated effector functions, respectively, with galactose having an auxiliary role for FcγRIII-mediated functions. This knowledge could be used not only for glycan profiling of clinically important (antigen-specific) IgG but also to optimize therapeutic antibody applications.

3 April 2017 in mAbs
Verified
Journal Article
Closed access
GDGillian Dekkers
Gillian Dekkers
ABArthur E. H. Bentlage
Arthur E. H. Bentlage
TSTamara C. Stegmann
Tamara C. Stegmann
HHHeather L. Howie
Heather L. Howie
SLSuzanne Lissenberg-Thunnissen
Suzanne Lissenberg-Thunnissen
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
Human IgG is the main antibody class used in antibody therapies because of its efficacy and longer half-life, which are completely or partly due to FcγR-mediated functions of the molecules. Preclinical testing in mouse models are frequently performed using human IgG, but no detailed information on binding of human IgG to mouse FcγRs is available. The orthologous mouse and human FcγRs share roughly 60-70% identity, suggesting some incompatibility. Here, we report binding affinities of all mouse and human IgG subclasses to mouse FcγR. Human IgGs bound to mouse FcγR with remarkably similar binding strengths as we know from binding to human ortholog receptors, with relative affinities IgG3>IgG1>IgG4>IgG2 and FcγRI>>FcγRIV>FcγRIII>FcγRIIb. This suggests human IgG subclasses to have similar relative FcγR-mediated biological activities in mice.

22 November 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GDGillian Dekkers
Gillian Dekkers
RPRosina Plomp
Rosina Plomp
CKCarolien A. M. Koeleman
Carolien A. M. Koeleman
RVRemco Visser
Remco Visser
HHHans H. von Horsten
Hans H. von Horsten
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
Immunoglobulin G (IgG) mediates its immune functions through complement and cellular IgG-Fc receptors (FcγR). IgG contains an evolutionary conserved N-linked glycan at position Asn297 in the Fc-domain. This glycan consists of variable levels of fucose, galactose, sialic acid, and bisecting N-acetylglucosamine (bisection). Of these variations, the lack of fucose strongly enhances binding to the human FcγRIII, a finding which is currently used to improve the efficacy of therapeutic monoclonal antibodies. The influence of the other glycan traits is largely unknown, mostly due to lack of glyco-engineering tools. We describe general methods to produce recombinant proteins of any desired glycoform in eukaryotic cells. Decoy substrates were used to decrease the level of fucosylation or galactosylation, glycosyltransferases were transiently overexpressed to enhance bisection, galactosylation and sialylation and in vitro sialylation was applied for enhanced sialylation. Combination of these techniques enable to systematically explore the biological effect of these glycosylation traits for IgG and other glycoproteins.

19 June 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
SJStefan Jonsson
Stefan Jonsson
GSGardar Sveinbjornsson
Gardar Sveinbjornsson
APAitzkoa Lopez de Lapuente Portilla
Aitzkoa Lopez de Lapuente Portilla
BSBhairavi Swaminathan
Bhairavi Swaminathan
RPRosina Plomp
Rosina Plomp
KSKari Stefansson
Kari Stefansson

11 December 2014 in Blood
Verified
Journal Article
Closed access
PDF file
SNSietse Q. Nagelkerke
Sietse Q. Nagelkerke
GDGillian Dekkers
Gillian Dekkers
IKIwan Kustiawan
Iwan Kustiawan
FBFleur S. van de Bovenkamp
Fleur S. van de Bovenkamp
JGJudy Geissler
Judy Geissler
TKTaco W. Kuijpers
Taco W. Kuijpers
In immune thrombocytopenia and warm autoimmune hemolytic anemia, circulating immunoglobulin G (IgG)-opsonized blood cells are cleared from the circulation by macrophages. Administration of intravenous immunoglobulin (IVIg) can prevent uptake, but the exact working mechanism is not known. The prevailing theory from murine studies, which states that Fc-sialylated IgG alters the balance between activating and inhibitory Fc-gamma receptors (FcγRs) by inducing upregulation of the inhibitory FcγRIIb on effector macrophages, is currently debated. We studied phagocytosis of IgG-opsonized blood cells in a human system, assessing the effect of IVIg and blocking anti-FcγR F(ab′)2 fragments on uptake by monocyte-derived macrophages (both M1 and M2 macrophages). Phagocytosis was remarkably sensitive to administration of IVIg, but unexpectedly, recombinant Fc-sialylated IgG or sialic acid-enriched IVIg were equally active as unsialylated IgG fractions in mediating this inhibition, independent of FcγRIIb expression. Instead, IVIg inhibited phagocytosis by direct blockade of FcγRs. IgG fractions enriched for IgG dimers with enhanced avidity for FcγRs showed increased inhibition compared with monomeric IgG fractions. Together, our data demonstrate that inhibition of IgG-mediated phagocytosis in human macrophages by IVIg is dependent on the capacity to directly bind FcγRs but is independent of FcγRIIb or sialylation of the Fc fragment in the human setting. Key Points Phagocytosis of IgG-opsonized blood cells by human macrophages is inhibited by intravenous immunoglobulins. This inhibition is independent of IgG-Fc sialylation but improves with IgG preparations that bind FcγRs more avidly.